| BioLineRx is a late clinical-stage biopharmaceutical development company with a focus on oncology. Co.'s development and commercialization pipeline consists of two clinical-stage therapeutic candidates: motixafortide (BL-8040), a peptide for the treatment of stem cell mobilization, solid tumors and acute myeloid leukemia, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, Co. has a therapeutic product called BL-5010 for the treatment of skin lesions. We show 2 historical shares outstanding datapoints in our BLRX shares outstanding history coverage, used to compute BLRX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BLRX market cap history over the course of time is important for investors
interested in comparing BLRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BLRX versus a peer is one thing; comparing
BLRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BLRX can fluctuate over the course of history.
With this page we aim to empower investors researching BLRX by allowing them to research the BLRX market cap history.